The Adjacent Vessel Sign on Breast MRI: New Data and a Subgroup Analysis for 1,084 Histologically Verified Cases by Dietzel, Matthias et al.
178 Korean J Radiol 11(2), Mar/Apr 2010
The Adjacent Vessel Sign on Breast MRI: 
New Data and a Subgroup Analysis for
1,084 Histologically Verified Cases
Objective: The adjacent vessel sign (AVS) is a descriptor for differentiating
malignant from benign breast lesions on breast MRI (bMRI). This investigation
was designed to verify the previous reports on the diagnostic accuracy of AVS
and to assess correlation between AVS, histopathological diagnosis, lesion size
and lesion grade.
Materials and Methods: This study was approved by the local ethical commit-
tee. Experienced radiologists evaluated 1,084 lesions. The exclusion criteria
were no histological verification after bMRI and breast interventions that were
done up to one year before bMRI (surgery, core biopsy, chemo- or radiation ther-
apy). The native and dynamic contrast-enhanced T1-weighted series were
acquired using standardized protocols. The AVS was rated positive if a vessel
leading to a lesion could be visualized. Prevalence of an AVS was correlated with
the lesions’ size, grade and histology using Chi-square-tests. 
Results: The AVS was significantly associated with malignancy (p < 0.001;
sensitivity: 47%, specificity: 88%, positive-predictive-value [PPV]: 85%).
Malignant lesions > 2 cm more often presented with an AVS than did those malig-
nant lesions < 2 cm (p < 0.0001; sensitivity: 65%, PPV: 90%). There was no cor-
relation of the AVS with the tumor grade. The prevalence of an AVS didn’t signifi-
cantly differ between invasive lobular carcinomas versus ductal carcinomas. In
situ cancers were less frequently associated with an AVS (p < 0.001). 
Conclusion: The adjacent vessel sign was significantly associated with malig-
nancy. Thus, it can be used to accurately assess breast lesions on bMRI. In this
study, the AVS was particularly associated with advanced and invasive carcino-
mas. 
reast MRI (bMRI) is a well established method for making the diagnosis
of invasive breast cancer with sensitivity that approaches 100%, yet the
specificity rates have been reported to be lower (1-7). Therefore, the
current research on bMRI has focused on improving this parameter (8-14).
Several approaches have been suggested; additional sequences, such as diffusion
weighted imaging or MR spectroscopy, might add further information for making the
differential diagnosis (10, 11, 13, 14). A computer aided diagnosis (CAD) can be used
to evaluate bMRI and this might improve the diagnostic accuracy (8, 9).
Yet the drawback of these approaches is the additional scanning time and/or the
extra costs for the hard- and/or software. This is why further investigations have
focused on the analysis of the morphologic and dynamic descriptors to improve the
specificity of bMRI (1-3, 15, 16). One of these descriptors is the adjacent vessel sign
(AVS), which was previously described by our research group (1-3); the AVS is
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Bpositive if one or more vessels leading to a lesion can be
visualized on the T1 weighted sequences after the applica-
tion of contrast media, and this indicates malignancy. To
the best of our knowledge, the correlation of the AVS with
the histological subgroups, the tumor size and the tumor
grade has not been performed in a large study (1-3).
Therefore, this blinded, prospective study of the previously
acquired examinations of 1,084 histologically verified
lesion was designed to 1) verify the previous reports on the
diagnostic accuracy of AVS and 2) assess the correlation
between the AVS, the histopathological diagnosis, the
lesion size and the grade of the lesion. 
MATERIALS AND METHODS
The Patients and Lesions
This study was approved by the local ethics committee.
All the patients gave us their written consent for the
examination. This study was based on a database that
contained all the consecutive bMRI performed at our
institution over the previous 12 years. Subsets of this
database have been addressed in previous investigations
by our team, e.g. (17). All the patients were referred by
the Clinic of Gynecology of our university. According to
the standards of our clinical routine practice, the indica-
tions for bMRI were: (a) unclear findings (e.g. Breast
Imaging Reporting and Data System [BI-RADS] III) on X-
ray mammography and/or ultrasound, and (b) preopera-
tively staged BI-RADS IV or BI-RADS V lesions. 
Only those lesions with histopathological verification at
the Department of Pathology of our university after bMRI
were eligible for this study. In order to eliminate any
possible post-therapeutical artifacts, all the patients with a
history of surgical or minimal invasive breast biopsy and
chemo or radiation therapy up to one year before
undergoing bMRI were excluded. Therefore, the BI-RADS
VI lesions were not eligible for this investigation. Due to
this strict study protocol, 1,012 patients were included into
this study. 
Imaging
Dedicated bilateral breast coils with the patient lying in
the prone position were used for image acquisition
(Phillips: Intera/GyroscanACSII; Siemens:
Symphony/VisionPlus). All the bMRIs were performed by
scanners at 1.5 T field strength (Table 1). We used
standardized protocols for the axial plane images, starting
with the dynamic T1-weighted gradient echo sequences
(Phillips: FFE; Siemens: GRAPPA; all 2D). Initially, one
native scan was acquired, and this was followed by a bolus
injection (3 ml/s) of Gd-DTPA (Magnevist, Bayer
HealthCare, Leverkusen, Germany; 0.1 mmol/kgbw).
Thirty seconds after bolus injection, the  dynamic scanning
was continued with the same sequence parameters under
identical tuning conditions at 1-minute intervals for a total
of 8 minutes. Commercially available software provided
by the vendor was used to process the subtractions of the
Adjacent Vessel Sign on Breast MRI and Histopathologic Subgrouping
Korean J Radiol 11(2), Mar/Apr 2010 179
Table 1. Scan Parameters for Axial T1 Weighted Contrast
Enhanced Images
Scan Parameters
Intera/Gyroscan  Vision Symphony/
ACS II
� Plus* Sonata*
TR (ms) 97 220 113
TE (ms) 5.0 4.7 4.6
Flip Angle (� )8 0 7 5 8 0
Slice thickness (mm) 4 4 3
Field of View (mm) 350 350 350
Slice number 24 24 33




Fig. 1. Adjacent vessel sign: schematic drawing. Right breast
shows vessel leading directly to solid lesion. In this case,
adjacent vessel sign is positive. Contralateral breast shows solid
lesion. No adjacent vessel is visualized and adjacent vessel sign
is negative.
Fig. 2. Invasive cancer of left breast demonstrating positive
adjacent vessel sign. Adjacent vessel is visualized leading
directly to lesion in subtraction image obtained 1 minute after
application of contrast agent.pre-contrast dynamic images from the postcontrast
dynamic images. The technical details of the protocol are
listed in Table 1.
Histopathological Workup
Only those lesions that were histologically verified at the
Department of Pathology at our university were included
in the study. Histopathological verification was performed
by experienced breast pathologists. The benign breast
lesions were divided into the following subcategories:
a) Solid benign tumors: Fibroadenoma, phyllodes tumor,
papilloma
b) Inflammatory conditions: Mastitis, galactophoritis
c) Benign proliferative findings, e.g. fibrocystic changes. 
Malignant lesions were histopathologically classified by a
board certified pathologist according to the World Health
Organization (WHO) classification of breast carcinoma.
The Elston-Eillis method was used for grading. It was
performed to classify the histological grading as G1 (‘well
differentiated’), G2 (‘intermediate differentiated’) or G3
(‘poorly differentiated’) (18). 
Image Analysis
The AVS was visually assessed on the subtracted dynamic
contrast-enhanced T1-weighted sequences. It was rated
positive if a vessel leading to a lesion could be clearly
delineated on any of the subtraction scans (Figs. 1- -6). 
To assure that our readers had a high level of experience,
only radiologists (n = 6) who specialized in bMRI and had
performed at least 500 bMRI were eligible for image
analysis. Before the evaluation was initiated, all the
readers completed a one week training session together to
optimize the assessment of the descriptor and to minimize
the inter/intraobserver variability. Two readers evaluated
the presence of the AVS by working in consensus. For the
cases of unclear classification, the AVS was rated as
negative.
The readers were blinded to the histopathological
outcome. The maximum diameter of all the lesions was
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Fig. 3. Example of false negative adjacent vessel sign. Invasive
cancer of left breast without adjacent vessel sign. No adjacent
vessels could be visualized after application of contrast agent.
Fig. 4. Example of false positive adjacent vessel sign. Adjacent
vessel (arrow) is clearly delineated 1 minute after application of
contrast media, as shown on this subtraction image. Proportion of
false positive adjacent vessel signs was small, consisting of 54 of
1,084 lesions.
Fig. 6. Benign phyllodes tumor of left breast. Adjacent vessel can
be clearly delineated on subtraction images obtained 1 minute
after application of contrast agent (Gd-DTPA). This is example of
false positive adjacent vessel sign.
Fig. 5. Invasive cancer of left breast. This subtraction image
obtained 1 minute after application of contrast agent illustrates
advanced cancer with adjacent vessel that directly feeds tumor
through pectoral wall. This is example of true positive adjacent
vessel sign.measured on the MR images using electronic scales or
calipers. According to the maximum diameter of the
lesions on the contrast enhanced T1-weighted sequences,
we dichotomized the studied lesions into two groups of
small (1-20 mm) and locally advanced (> 21 mm) lesions.
Statistical Analysis
We used Excel 2003 (Microsoft, Redmond, WA) and
SPSS 15 for Windows (SPSS, Chicago, IL) for data collec-
tion and analysis. Two-sided Pearson’s chi-square tests
were applied to test for significant differences between the
prevalence of the AVS in each subgroup. Fisher’s exact test
was used if one or more cells showed an expected count
less than 5. P values smaller or equal to 0.05 were
regarded as significant, and those p values less than 0.001
were regarded as highly significant. If the p values were <
0.1 and > 0.05, then they were interpreted as a trend.
The diagnostic accuracy of the AVS was evaluated using
standard statistical parameters, including the sensitivity,
specificity and positive predictive value (PPV). As the
pretest probability can influence the standard predictive
values, we additionally calculated the advanced statistical
parameters. As these are not dependent on the pretest
probability within the given subgroups, they were chosen
to compare the diagnostic accuracy of the AVS between
subgroups. The advanced statistical parameters included
the positive/negative likelihood ratios (LR+/-) and the
diagnostic odds ratios (DOR). 
To further address the pretest probability within
subgroups, the relative prevalence of the AVS was comple-
mented by the 95%-confidence intervals (CI) for assessing
the presence of this descriptor (19-21).
RESULTS
Patients and Lesions
Following the above stated criteria. 1,012 patients who
showed 1,084 histologically verified lesions were included
into this study (mean: 55.5 year, range: 16-91 years,
standard deviation: 13.1 years). The data published by
Malich et al. (3) (641 lesions) and Fischer et al. (1, 2) (132
lesions, including 32 with a recent history of chemotherapy
and core biopsy) represents the subgroups of our study
collective. 
The Overall Prevalence and Diagnostic Accuracy
The AVS was diagnosed in 33% of all the lesions (360 of
1,084). The malignant lesions exhibited this sign highly
significantly more often than did the benign ones (p <
0.001). The overall accuracy of the AVS with applying the
standard and advanced statistical parameters, as well as the
performance within subgroups, is summarized in Tables 2
and 3. 
Malignant Subgroups
Sixty percentages of all the lesions were histologically
confirmed as malignant (648 of 1,084). 64% were smaller
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Table 2. Basic Parameters to Assess Diagnostic Accuracy of Adjacent Vessel Sign
Collective Sensitivity (%) Specificity (%) Positive Predictive Value (%)
Size ≤ 20 mm 37 89 80
> 20 mm 65 83 90
Histology In situ cancer 27 30
Invasive ductal 54 88 78
Invasive lobular 47 49
GradingG1 44 33
G2 47 88 69
G3 56 69
All 47 88 85
Table 3. Advanced Parameters to Assess Diagnostic
Accuracy of Adjacent Vessel Sign
Collective DOR  LR+  LR-
Size ≤ 20 mm 4.7 3.3 0.7
> 20 mm 9.2 3.9 0.4
Histology In situ cancer 2.7 2.2 0.8
Invasive ductal 8.4 4.4 0.5
Invasive lobular 6.3 3.8 0.6
GradingG1 5.5 3.5 0.6
G2 6.4 3.8 0.6
G3 9.1 4.5 0.5
All 6.3 3.8 0.6
Note.─ DOR = diagnostic odds ratios, LR+ = positive likelihood ratios 
LR- = negative likelihood ratios or equal to 20 mm (416 of 648) and 36% measured more
than 20 mm in diameter (232 of 648). 87% of all the
malignant lesions were invasive cancers (564 of 648), 62%
of this subgroup were invasive ductal cancers (347 of 564),
whereas 19% consisted of invasive lobular cancers (108 of
564). As demonstrated in Table 4, the less frequent invasive
tumor entities such as invasive tubular, papillary, mucinous
and medullary tumors were summarized as ‘other’ invasive
cancers (109 of 564: 19%). 13% of all the malignant lesions
were in situ cancers (84 of 648). Out of these, 82% were
pure ductal carcinomas in situ (DCIS: 69 of 84), 8% were
pure lobular carcinomas in situ (LCIS: 7 of 84) and 10%
were DCIS with LCIS components (8 of 84). 
The AVS was present in 47% of all the malignant lesions
(306 of 648). Table 4 summarizes the prevalence of the
AVS in the malignant subgroups. There was no significant
difference between the prevalence of the AVS on compar-
ing the invasive ductal versus lobular cancers (p = 0.21).
The difference between the incidence of the AVS on
comparing in situ versus invasive neoplasia of the breast
was highly significant (p < 0.001). Pure DCIS exhibited the
AVS in 30% (21 of 69), compared to 25% of the DCIS
with LCIS components (2 of 8). The AVS could not be
demonstrated in any case of the pure LCIS. 
Grading
Definite grading was possible upon histological examina-
tion for 532 of all the invasive carcinomas (Table 5). 12%
were G1 (62 of 532), 48% were G2 (253 of 532) and 41%
were G3 lesions (217 of 532). The correlation of the AVS
and the grading was not significant. Yet, there was a trend
towards a higher prevalence of the AVS for the poorly
differentiated breast carcinomas (G1 versus G3: p = 0.08;
G2 versus G3: p = 0.06). 
Benign Subgroups
The histopathological diagnosis was benign in 40% of all
the cases (436 of 1,084). 78% of all the benign lesions
were ≤ 20 mm (341 of 436). 45% of the benign lesions
were solid tumors (196 of 436), 24% of all the benign
lesions were fibroadenomas (103 of 436), 19% were
papillomas (83 of 436) and 2% were phyllodes tumors (10
of 436). Concerning the non solid benign lesions, 51%
were fibrocystic changes (220 of 436) and 5% were
inflammations (20 of 436). 
The AVS was present in 12% of all the benign lesions
(54 of 436). Table 6 summarizes the prevalence of this
descriptor in the benign subgroups. The benign diagnoses
that exhibited the AVS most frequently were inflamma-
tory changes (6 of 20) and phyllodes tumors (3 of 10), and
both exhibited the AVS in 30%. However, these differ-
ences were only significant regarding the inflammatory
changes (p < 0.05). 
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Table 4. Adjacent Vessel Sign in Malignant Subgroups
Histology AVS (%) CI (%)
Carcinoma in situ 0023 / 840 (27)0 19 - 38
Invasive ductal 188 / 347 (54) 49 - 59
Invasive lobular 051 / 108 (47) 38 - 57
Other invasive cancers* 044 / 109 (40) 32 - 50
Total 306 / 648 (47) 43 - 53
Note.─ *: Less frequent invasive tumor entities such as invasive tubular, 
papillary, mucinous and medullary carcinoma.
AVS = adjacent vessel sign, CI = confidence interval
Table 5.  Prevalence of Adjacent Vessel Sign as Correlated
with Grading of Invasive Breast Cancers
� �
AVS AVS (%) CI (%)
G1 0027 / 620 (44)0 32 - 56
G2 120 / 253 (47) 42 - 54
G3 122 / 217 (56) 50 - 63
P value*  n.s.
Note.─
�: In 532 of all invasive carcinomas, definite grading was possible 
upon histological examination.
*: G1 vs. G2, G1 vs. G3, G1 vs. G2+G3; G2 vs. G3
AVS = adjacent vessel sign, CI = confidence interval
Table 6. Adjacent Vessel Sign in Benign Subgroups
Histology AVS (%) CI (%)
Fibroadenoma 009 / 1030 (9)00 5 - 16
Phyllodes tumors 003 / 100 (30)0 11 - 60
Papilloma 011 / 830 (13)00 8 - 22
Inflammation  006 / 200 (30)0 15 - 52
Fibrocystic changes 25 / 220 (11) 08 - 16
Total 54 / 436 (12) 10 - 16
Note.─ AVS = adjacent vessel sign, CI = confidence interval
Table 7. Adjacent Vessel Sign in Benign and Malignant
Lesions as Correlated with Lesions’ Size
Subgroup AVS (%) CI (%)
Benign (≤ 20 mm) 038 / 341 (11) 08 - 15
Benign (> 20 mm) 0016 / 950 (17)0 11 - 26
P value n.s.
Malignant (≤ 20 mm) 155 / 416 (37) 33 - 42
Malignant (> 20 mm) 151 / 232 (65) 59 - 71
P value < 0.001
Note.─ AVS = adjacent vessel sign, CI = confidence intervalSize
The proportion of malignant lesions was 71% within the
lesions > 20 mm (232 of 327) and 55% for the lesions ≤
20 mm (416 of 757). This difference was highly significant
(p < 0.001). The prevalence of the AVS was 26% for the
lesions smaller or equal to 20 mm (193 of 757), whereas
this sign was present in 51% of all lesions > 20 mm (167 of
327; p < 0.001). The prevalence of AVS, as correlated with
the lesion size and histology, is summarized in Tables 7
and 8. 
DISCUSSION
In the current study we demonstrated that the AVS is
significantly more often found in malignant lesions than in
benign lesions, and the AVS exhibited a specificity of 88%
and a PPV of 85%. The invasive ductal and lobular
carcinomas - the most common neoplasia - presented the
AVS with a similar frequency. However, this feature was
observed significantly less frequently in the preinvasive
cancers. 
The previous publications from our group with different
study designs and smaller patient cohorts were in good
agreement with the current results (1-3). Malich et al. (3)
reported a specificity of 72% (155 of 215) and a PPV of
82% (268 of 328) for the AVS on 641 lesions. As that
previous investigation was designed to evaluate a potential
interpretation model for bMRI, no detailed analysis of the
subgroups was published by Malich and co-workers. Yet
this was done by Fischer et al. (1) on a cohort of 132
lesions. They found specificity rates of 80% and a PPV of
87%. However, in that investigation, lesions with a history
of core biopsy and radiation- or chemotherapy were
included. Basically, any intervention of the breast might
cause inflammation (24). As a result, hyperemia and vessel
dilatation can occur, and both pose the risk of mimicking
AVS (22, 24). Therefore, the prevalence of this feature in a
post therapeutic setting could be increased (24). As these
physiological reactions might impose bias for the evalua-
tion of AVS, we excluded all the lesions with a history of
intervention, chemotherapy or radiation up to one year
before the bMRI. 
This is why we designed this investigation to further
evaluate the AVS. Due to the larger collective of 1,084
cases, it was possible to statistically validate the subgroups
and to correlate the AVS versus the histopathological
diagnosis and the grading of invasive carcinomas.
Our findings underline the important role of neoangio-
genesis for the development of breast neoplasia (23). It is
well known from experimental studies that expansive
tumor growth needs neovascularization in order to supply
itself with oxygen and nutrients (24-26). This is why the
AVS could be interpreted as an indicator of neovascular-
ization in malignant tumors (1). Preinvasive tumors may
show a decreased level of neoangiogenesis (24, 27, 28).
This is a possible explanation why the AVS was seen
significantly less frequently in the preinvasive cancers
compared to the invasive cancers, and this resulted in a
lower sensitivity when comparing preinvasive cancers
versus invasive cancers (7, 27, 28).
Although AVS was significantly more frequently visual-
ized in the malignant tumors compared to the benign
tumors, there were also false positive cases in the current
study (54 of 1,084). These were mainly solid benign
tumors (in particular papillomas and phyllodes tumors) and
inflammatory changes (24). It is well known from
histopathological studies that not only malignant tumors,
but also benign tumors induce angiogenesis, yet this is less
pronounced for the benign tumors (29). This process could
serve as the histopathological basis for the false positive
AVS cases in solid tumors. Similarly, inflammatory
changes might cause a false positive AVS as well.
Inflammatory conditions are known to cause hyperemia
and vessel dilatation (24). Such physiological reactions
might be a possible explanation for the high prevalence of
the AVS in benign inflammatory changes. Notably, the
largest subgroup of our benign subset was fibrocystic
changes. According to the data published by Langer et al.
(22) this subgroup contributes the majority of false positive
bMRI examinations. Considering that the AVS showed a
significantly lower prevalence in the fibrocystic changes, as
compared to the remaining benign lesions, this sign might
decrease the false positive MRI mammograms in this
context. 
Our analysis didn’t show any significant correlation
between the AVS and the tumor grade. Invasive breast
cancers are known to initiate neoangiogenesis at an early
stage (24, 30, 31). This might explain why the AVS was
already positive in the well differentiated early stage
tumors. As the AVS is feasible to assess lesions irrespective
of the nuclear grading, it should be considered as a useful
tool to make the differential diagnosis using bMRI.
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Table 8. Size-Matched Subgroup Analysis of Adjacent





Benign (%) Malignant (%)
≤ 20 mm 38 / 341 (11) 155 / 416 (37) < 0.001
> 20 mm 016 / 950 (17)0 151 / 232 (65) < 0.001
Note.─ AVS = adjacent vessel sign, CI = confidence intervalThe AVS could be visualized significantly more often in
malignant tumors exceeding 2 cm in size, as compared to
those malignant tumors smaller or equal to 2 cm.
However, when comparing the small benign tumors (≤ 20
mm) with the benign tumors > 20 mm, only a slight, but
not statistically significant increase of the AVS’s prevalence
was observed. The clinical value of these findings is the
higher potential for making the differential diagnosis of
advanced lesions compared to small lesions with a DOR of
9.2. However, the positive likelihood ratios didn’t signifi-
cantly differ between the small and advanced lesions (3.3
versus 3.9). This demonstrates the potential of the AVS for
making the differential diagnosis for lesions ≤ 20 mm. The
reason for the higher prevalence of the AVS in tumors 
> 20 mm is probably the higher angiogenetic activity of
such lesions according to the higher demand for nutrients
and oxygen. However, it should be considered as well that
very small vessels might be missed on bMRI due to the
partial volume effects (16) and so the sensitivity of the
AVS for tumors < 20 mm is decreased. A smaller slice
thickness and/or higher resolution might be one approach
to solve this issue. As our rationale was to evaluate the
morphologic descriptors of bMRI by using a well
established standard protocol in a standard clinical setting,
we did not apply the high resolution sequences. 
As stated above, certain benign lesions require neoangio-
genesis as well, following the same basic principles as those
for malignant tumors (24, 29, 30). However, tumor growth
and cellular turnover are much lower in benign tumors,
resulting in a lower demand for nutrients (24, 29, 30).
These findings could explain why on the one hand benign
tumors sometimes presented with an AVS, but on the
other hand they didn’t show any significant correlation of
the AVS and tumor size.
Finally, some critical aspects and limitations of this study
should be addressed. The AVS was visually rated by
experienced radiologists on a nominal scale. Morphologic
descriptors such as the AVS are ultimately subjective
parameters and they are susceptible to intra- and interob-
server variability (21). To decrease bias due to intra- and
interobserver variability, the study design was as follows:
1) The AVS was defined as precise and as straightforward
as possible to enhance the understandability and applica-
bility. 2) Diagnosing an AVS was done by two experienced
readers working in consensus. 3) The level of experience of
the readers was kept as high as possible and only radiolo-
gists who had performed at least 500 bMRI were eligible.
4) Before the evaluation was initiated, the readers
completed a one week training session to optimize the
assessment of the descriptor and to minimize the
inter/intraobserver variability. 
From previous studies it is well known that the morpho-
logic characteristics seen on bMRI, when assessed in a
standardized way using descriptors, provide vital informa-
tion for making an accurate differential diagnosis (4). This
is why all the major interpretation systems of bMRI have
included morphologic descriptors (3, 32, 33). However, the
intra- and interobserver variability could decrease the
reproducibility of morphologically assessing bMRI.
According to the design of this investigation as a consensus
study, systematic evaluation of the intra- and interobserver
variability was not possible (21). This should be the
rationale of future investigations that will address the inter-
and intraindividual reproducibility of morphologic descrip-
tors. 
Assessing the diagnostic accuracy depends on the pre-
test probability (21). Thus, if the routine of referral for
bMRI is altered, then our results might not be
reproducible. However, this must be taken into account for
every clinical trial dealing with diagnostic accuracy and this
problem cannot be solved completely. In our practice,
bMRI usually is the last diagnostic test for working up
women with breast disease (34). This explains why the pre-
test probability for detecting breast cancer on bMRI was
much higher in our practice than it would be in a screening
setting. In this study, histological verification was
performed after bMRI. This is in accordance with our
common practice. In other centers, the routine for referral
might be different, and bMRI might be preferably
performed after histological verification of the BI-RADS VI
lesions. Furthermore, as reported by Liberman et al. (35)
the pretest probability of malignancy correlates with the
size of the lesion seen on bMRI. This explains why the
proportion of malignant lesions in our collective was signif-
icantly higher within the subgroup of lesions > 20 mm as
compared to those ≤ 20 mm. 
To solve this issue, the pretest probability should be
addressed by choosing appropriate statistics. Standard
predictive values critically depend upon the pretest
probability and so they should be interpreted with care.
This is why we applied advanced parameters that are
independent of pretest probability to assess the diagnostic
accuracy of AVS (21). Thus, the bias due to different
pretest probability was decreased and the parameters L+/-
and DOR could be compared directly between the
subgroups without a selection bias. 
This study addresses the diagnostic accuracy of AVS as a
single descriptor. If a new diagnostic test is evaluated, it is
reasonable to assess diagnostic accuracy as a single assess-
ment approach. If the evidence as a single diagnostic test is
sufficient, then this test should be evaluated in combination
with the standard methods. Thus, the incremental value of
Dietzel et al.
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evidence for the AVS as a single diagnostic test is still
limited, this study addressed the diagnostic accuracy of the
AVS as a single descriptor. Consequently, the incremental
value of the AVS cannot be estimated according to our
study. This is why future studies should focus on this issue.
Such investigations might address the diagnostic accuracy
of bMRI using standard criteria, such as an MRI BI-RADS
lexicon with and without AVS (16).
In conclusion, the AVS has high potential to differentiate
benign breast lesions from malignant breast lesions on
bMRI (specificity: 88%; L+: 3.8). The AVS was particularly
accurate for evaluating advanced lesions (DOR 9.2).
However, the likelihood of malignancy was high in small
and advanced lesions (L+ 3.3 versus 3.9). The correlation
revealed the potential to accurately characterize invasive
breast carcinomas, even if the cancer was still well differ-
entiated.
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